Table 2.
General Rh-factor testing and ultrasound policies in February and October 2020 as reported by survey respondent sites in the US, by region and site typea
| Northeastbn = 19 | Westn = 15 | Southn = 12 | Midwestn = 8 | |
|---|---|---|---|---|
| Rh-factor testing required for all patients prior to medication abortion-February | 16 (84%) | 14(93%) | 12 (100%) | 8 (100%) |
| Rh-factor testing required for all patients prior to medication abortion-October | 5 (26%) | 1 (7%) | 5 (42%) | 4 (50%) |
| Northeastn = 20 | Westn = 15 | Southn = 12 | Midwestn = 8 | |
| Ultrasound testing required for all patients prior to medication abortion-February | 20(100%) | 15 (100%) | 12 (100%) | 8 (100%) |
| Ultrasound required for all patients prior to medication abortion-October | 15 (74%) | 8 (53%) | 10 (83%) | 7 (88%) |
| Academic/hospital-based*n=25 | Independentn=14 | Planned Parenthood affiliaten=15 | ||
| Rh-factor testing required for all patients prior to medication abortion-February | 23 (92%) | 12 (86%) | 15 (100%) | |
| Rh-factor testing required for all patients prior to medication abortion-October | 7 (28%) | 6 (43%) | 2 (13%) | |
| Academic/hospital-basedn = 26 | Independentn = 14 | Planned Parenthood affiliaten = 15 | ||
| Ultrasound testing required for all patients prior to medication abortion-February | 26 (100%) | 14 (100%) | 15 (100%) | |
| Ultrasound testing required for all patients prior to medication abortion-October | 20 (76%) | 12 (86%) | 8 (53%) | |
a
Reported as n(%).
b
One academic/hospital-based site in the Northeast did not report Rh-factor testing in October and is omitted from this table for Rh-factor policies.